Core Insights - Profound Medical Corp. has achieved a significant milestone with the completion of its 500th Sonalleve Procedure at PRO FAMILIA Specialist Hospital in Poland, reflecting the growing adoption of non-surgical treatment options for uterine conditions [1][2] - The Sonalleve technology offers a non-invasive alternative for treating uterine fibroids and adenomyosis, providing targeted relief without incisions, blood loss, or the need for overnight hospital stays [1][2] - The company is also focused on the commercialization of TULSA-PRO, which is designed for prostate disease treatment, emphasizing its unique ability to minimize side effects associated with traditional surgical methods [3][5] Company Overview - Profound Medical Corp. is a commercial-stage medical device company that specializes in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [4] - The company is actively commercializing two main products: TULSA-PRO for prostate conditions and Sonalleve for gynecologic disorders, both of which utilize advanced imaging and therapeutic technologies [5][7] Product Details - Sonalleve has been operational in Europe, China, and Southeast Asia, with over 4,000 women treated for uterine conditions, demonstrating effective pain and symptom relief while preserving fertility [2][3] - TULSA-PRO employs real-time MRI guidance and is designed to treat a wide range of prostate diseases, ensuring preservation of urinary continence and sexual function [5][6] - Both Sonalleve and TULSA-PRO have received various regulatory approvals, including CE marking and FDA clearance, indicating their compliance with safety and efficacy standards [6][7]